Literature DB >> 14696344

Development of lymphoid lineages from embryonic stem cells in vitro.

Sarah K Cho1, Juan Carlos Zúñiga-Pflücker.   

Abstract

Lymphocyte development proceeds through highly ordered and regulated stages, as multipotent hematopoietic progenitors differentiate into lineage-defined progenitors, and ultimately into mature effector cells. The ability to generate lymphocytes from embryonic stem (ES) cells in vitro should facilitate the study of these complex differentiation steps by providing a model system in which the effects of genetic and nongenetic manipulations can be examined in a controlled setting. These advances may also contribute to future therapeutic approaches. In this article, we describe the procedure for generating functional lymphocytes from mouse ES cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14696344     DOI: 10.1016/s0076-6879(03)65011-1

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  9 in total

1.  A developmentally controlled competitive STAT5-PU.1 DNA binding mechanism regulates activity of the Ig κ E3' enhancer.

Authors:  Suchita Hodawadekar; Kyoungsook Park; Michael A Farrar; Michael L Atchison
Journal:  J Immunol       Date:  2012-01-25       Impact factor: 5.422

Review 2.  Advances in cellular technology in the hematology field: What have we learned so far?

Authors:  Gustavo Torres de Souza; Claudinéia Pereira Maranduba; Camila Maurmann de Souza; Danielle Luciana Aurora Soares do Amaral; Francisco Carlos da Guia; Rafaella de Souza Salomão Zanette; João Vitor Paes Rettore; Natana Chaves Rabelo; Lucas Mendes Nascimento; Ícaro França Navarro Pinto; Júlia Boechat Farani; Abrahão Elias Hallack Neto; Fernando de Sá Silva; Carlos Magno da Costa Maranduba; Angelo Atalla
Journal:  World J Stem Cells       Date:  2015-01-26       Impact factor: 5.326

Review 3.  Designer blood: creating hematopoietic lineages from embryonic stem cells.

Authors:  Abby L Olsen; David L Stachura; Mitchell J Weiss
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113

4.  Knockdown of Pu.1 by small interfering RNA in CD34+ embryoid body cells derived from mouse ES cells turns cell fate determination to pro-B cells.

Authors:  Gang-Ming Zou; Jian-Jun Chen; Mervin C Yoder; Wei Wu; Janet D Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-01       Impact factor: 11.205

Review 5.  Challenges and strategies for generating therapeutic patient-specific hemangioblasts and hematopoietic stem cells from human pluripotent stem cells.

Authors:  Ann Peters; Paul W Burridge; Marina V Pryzhkova; Michal A Levine; Tea-Soon Park; Christopher Roxbury; Xuan Yuan; Bruno Péault; Elias T Zambidis
Journal:  Int J Dev Biol       Date:  2010       Impact factor: 2.203

6.  Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cells.

Authors:  Hiroshi Watarai; Shin-ichiro Fujii; Daisuke Yamada; Andrei Rybouchkin; Sakura Sakata; Yuko Nagata; Midori Iida-Kobayashi; Etsuko Sekine-Kondo; Kanako Shimizu; Yohei Shozaki; Jafar Sharif; Masashi Matsuda; Shinobu Mochiduki; Takanori Hasegawa; Genta Kitahara; Takaho A Endo; Tetsuro Toyoda; Osamu Ohara; Ken-ichi Harigaya; Haruhiko Koseki; Masaru Taniguchi
Journal:  J Clin Invest       Date:  2010-07       Impact factor: 14.808

7.  A mutation in a chromosome condensin II subunit, kleisin beta, specifically disrupts T cell development.

Authors:  Katharine M Gosling; Lydia E Makaroff; Angelo Theodoratos; Yong-Hee Kim; Belinda Whittle; Lixin Rui; Hua Wu; Nancy A Hong; Gavin C Kennedy; Julie-Anne Fritz; Adele L Yates; Christopher C Goodnow; Aude M Fahrer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-17       Impact factor: 11.205

Review 8.  Experimental limitations using reprogrammed cells for hematopoietic differentiation.

Authors:  Katharina Seiler; Motokazu Tsuneto; Fritz Melchers
Journal:  J Biomed Biotechnol       Date:  2011-11-30

Review 9.  Autologous blood cell therapies from pluripotent stem cells.

Authors:  Claudia Lengerke; George Q Daley
Journal:  Blood Rev       Date:  2009-11-11       Impact factor: 8.250

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.